Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Zscaler Inc (ZS) vs Zoetis Inc (ZTS) Price & Performance

Zscaler IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Zscaler Inc vs Zoetis Inc — how do they compare? Zscaler Inc trades at $233.73 (market cap $35.35B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zscaler Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Zscaler Inc for 41 Days and Zoetis Inc for 70 Days on average.

ZSZTS
Market Cap
$35.35B$30.20B
Volume
3,726,2036,175,327
Sector
TechnologyHealth
52-Week High
$336.27$147.53
52-Week Low
$118.05$69.09
Typical Hold Time
41 Days70 Days
Enterprise Value
$33.73B$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Zscaler Inc

Zscaler (ZS) trades at $233.73, up 9.45% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day, while analyst sentiment is overwhelmingly positive with 79.6% buy ratings.

The stock offers growth potential driven by cybersecurity demand and AI product adoption, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target of $222.83 suggests modest downside from current levels, requiring careful risk assessment amid volatile market conditions.

Zoetis Inc

Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.

Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ZS
52% Buy48% Sell
Avg holding period · 41 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →